Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Recruiting 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2NET 1Endocrine 1

Conditions

Pancreatic Neoplasms 1Neuroendocrine Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoid Tumor 1Adenoma, Islet Cell 1

Interventions

Carboplatin 129pembrolizumab 124Cisplatin 114Paclitaxel 102Gemcitabine 85Specimen Handling 80Magnetic Resonance Spectroscopy 80Docetaxel 70Dexamethasone 59Cyclophosphamide 59Pemetrexed 55Bevacizumab 54durvalumab 53Doxorubicin 52Radiotherapy 49Capecitabine 49Radiation 47Oxaliplatin 47Fluorouracil 47Rituximab 42Leucovorin 42Vincristine 41Lenalidomide 40Etoposide 38Letrozole 36atezolizumab 35Nivolumab 35Prednisone 31Bortezomib 31130-nm albumin-bound paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × lanreotide × 90 days × Clear all
NCT06807437 2026-03-31

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

SWOG Cancer Research Network

Phase 3 Recruiting
274 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡